Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD) is a listed, clinical-stage biopharmaceutical company founded in 2007, dedicated to the discovery and development of vaccines and novel immunotherapies.

Our bold aim is to generate game-changing therapeutics to treat cancers and infectious diseases with a high unmet medical need. With our unique and innovative modular vaccine technology, we’re specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting immune responses.

Today we are counting more than 100 amazing multinational employees within medical and development teams, manufacturing, bioinformatics, and research departments. We utilize the Nykode Therapeutics' technology platform to generate novel treatments across therapeutics areas including oncology, infectious diseases, and immune tolerance. We closely collaborate with several pharmaceutical companies, and we are proud to have entered into a worldwide license and collaboration agreements with Genentech, a member of the Roche Group and Regeneron.